Abstract
BackgroundIpilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted an open-label,...
Highlights
Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action
We report the final results of clinical trial NCT01496807, an open label, phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable stage IV melanoma
We found that ipilimumab at 3 mg/kg plus peginterferon alfa-2b at 2 μg/kg weekly was the maximal
Summary
Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Treatment for metastatic melanoma has significantly evolved with the development and regulatory approval of several therapeutic classes of medications including both molecularly targeted and immunologically focused checkpoint inhibitor therapies. Despite these recent advances, limitations remain in the treatment of advanced melanoma. While offering the potential for durable responses, treatment with checkpoint inhibitor immunotherapies remain active in only a percentage of patients with advanced melanoma, and most patients will require further therapy [5,6,7]. Combination checkpoint inhibitor therapy is associated with high rates of response but is limited by severe toxicity in more than half of treated patients [8]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
